Sparsentan experience for IgA nephropathy in Switzerland
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study is collecting information from people in Switzerland who are already taking the drug sparsentan for IgA nephropathy, a kidney disease. Doctors want to learn more about how well the treatment works in everyday care, which may help improve future care for others.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of IgA nephropathy, a kidney disease.
- You need to be currently using the medication sparsentan.
- You must be 18 years or older.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called atrasentan to see if it helps protect kidney function in people with IgA nephropathy, a kidney disease. It may slow down kidney damage and reduce protein in the urine.
This trial tests two study medicines, zigakibart and atrasentan, together for adults with a kidney disease called IgA nephropathy. The goal is to see if this combination helps protect kidney function and reduces protein in the urine.
This trial tests a new medication for IgA nephropathy, a kidney disease that causes inflammation and protein loss in urine. It aims to see if the drug can safely slow down kidney damage and protect kidney function.
This trial tests an experimental drug (SC0062 capsule) for people with IgA nephropathy who have protein in their urine. It aims to see if the drug can help reduce kidney damage when added to standard treatments like blood pressure medications.
This trial tests an experimental tablet, HSK39297, for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and can help reduce protein in the urine, which is a sign of kidney damage.
This study observes how people with IgA nephropathy respond to standard and newer treatments in everyday medical practice, to understand why some cases are resistant to therapy.
Hear when a new IgA Nephropathy (IgAN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.